Question 1

What is ankylosing spondylitis, in plain terms?

Accepted Answer

Ankylosing spondylitis is a form of arthritis where the immune system inflames the joints where the spine meets the pelvis, and sometimes the spine itself, the eyes, the gut and the skin. Over years, inflammation can be followed by new bone that stiffens the spine, which is where the name comes from. Most people who have it carry a gene called HLA-B27, though most people with the gene never get AS, so other triggers, including the gut, are involved. Researchers now use the broader term axial spondyloarthritis, or axSpA, for the whole spectrum, with AS as its X-ray-visible end.

Question 2

Why did it take so long to get diagnosed?

Accepted Answer

The delay between first symptoms and a diagnosis is typically several years, and in some countries over a decade, because back pain is common, the early signs are easy to put down to something mechanical, and the scans can be read either way. A third of local diagnoses were overturned when experts re-read the scans in one large study, in both directions. Referral rules built on the features that actually predict AS, and tighter definitions of what counts as a positive MRI, are the two changes aimed squarely at this.

Question 3

Does being diagnosed early actually change anything?

Accepted Answer

For a long time the honest answer was that early and late-diagnosed patients responded to treatment about the same in the short term. A Swiss registry that followed people for over a decade has now shown that those diagnosed within two years of symptoms developed less spinal fusion on X-ray than those diagnosed later. That is the strongest argument yet for pushing for an answer rather than waiting.

Question 4

Which treatment comes first, and what comes after?

Accepted Answer

Current guidelines start with anti-inflammatory tablets and exercise, and move to an injected biologic, either a TNF blocker or an IL-17 blocker, or to an oral JAK inhibitor, when disease stays active. All three drug classes control symptoms; the evidence for slowing spinal damage is longest for TNF blockers and still accumulating for the others. The Korean 2026 guideline and the SPARTAN 2026 review give the clearest current picture of that sequence, including switching and tapering.

Question 5

Will my spine fuse, and can treatment stop it?

Accepted Answer

Not everyone fuses, and treatment appears to slow it: people on bimekizumab showed almost no X-ray progression over two years, and early diagnosis is linked to less damage decades later. The surprise in recent research is that new bone forms partly on its own track, driven by worn-out stem cells, rare gene variants and a protein signature that classic inflammation markers miss. That is why some people fuse despite well-controlled disease, and why the next generation of drugs may target bone formation directly.

Question 6

What if a drug stops working, or never worked?

Accepted Answer

Roughly one in ten people with axial spondyloarthritis still have persistent symptoms after two or more biologics, but only a minority of those are truly resistant to drugs. Fibromyalgia, smoking and pain that is no longer inflammatory account for much of the rest, which changes what the next step should be. With TNF blockers, antibodies against the drug are common and measurable, and some immune-cell patterns during a failed biologic predict whether a switch will work.

Question 7

Are these drugs safe to stay on for years?

Accepted Answer

The largest real-world study, over 56,000 people followed for five years, found no increase in cancer with sustained TNF, IL-17 or JAK treatment, and people with AS who do get common cancers survive them as well as anyone else. Three-year data on bimekizumab showed no deaths or major heart events, with mild fungal infections the main side effect; JAK inhibitors showed no excess clots or heart attacks in spondyloarthritis trials, though those trials were small. Biologics do not change fracture risk; steroid tablets do.

Question 8

Does exercise really help, and which kind?

Accepted Answer

Pooling 59 randomised trials, every structured exercise type beat usual care on disease activity, function and pain, with Pilates, yoga and Qigong each strong on different measures and none clearly best. Sessions of an hour or less showed the clearest benefit on function. A six-week unsupervised home programme changed little, which is a useful reminder that duration and structure matter more than the choice of exercise.

Question 9

Does what I eat make a difference?

Accepted Answer

The gut is one of the most active areas of AS research: people with AS have a different mix of gut bacteria, and HLA-B27 itself appears to shape it. The direct evidence on diet is much thinner. One study linked ultra-processed food to higher disease activity, a large UK study found no link at all between salt and AS, and the probiotic trials so far are small and mixed. Nothing here replaces treatment; eating well is reasonable and unproven.

Question 10

Why is everyone so worried about me falling?

Accepted Answer

A spine that has fused behaves like a long bone: a simple fall that would bruise someone else can fracture it, and the fracture is often unstable. Trauma-centre data show people with AS need bigger operations and have higher in-hospital mortality after such injuries. The longer-term picture is better than most expect: four years on, most survivors of AS neck fractures live independently with mild pain, and half of those with spinal cord injury recovered fully.

Question 11

What about pregnancy?

Accepted Answer

Rheumatologists agree pregnancy is not discouraged in spondyloarthritis and that the disease often behaves during it. The gap is information: women report high worry about flares and uncertainty about biologics and delivery, and only a quarter of rheumatologists surveyed knew the pregnancy guidelines. The practical step is planning the conversation before conception, with someone who knows the drug-specific guidance.

Question 12

My eyes keep flaring. Is that connected?

Accepted Answer

Acute anterior uveitis, a painful red eye with light sensitivity, is the most common extra-joint manifestation of AS and shares its HLA-B27 biology; new research traces both to the same population of T cells. It needs same-day eye care each time. When choosing a biologic partly to protect the eyes, a head-to-head trial found adalimumab and under-the-skin infliximab equally good at preventing flares.

Question 13

I have gut problems too. Is that part of it?

Accepted Answer

Gut inflammation and AS travel together: spinal disease occurs in a large share of people with inflammatory bowel disease, joint symptoms often come first, and even people with AS and no gut symptoms frequently have subclinical gut inflammation. Immune cells appear to move between gut and joint, and the mix of gut bacteria differs in AS. Treatment has to work for both organs, which is why some drugs that help the spine are avoided when the bowel is involved.

Question 14

Does AS affect my heart or circulation?

Accepted Answer

Long-running inflammation raises cardiovascular risk, and recent large studies add two specifics: people with AS had a 40 percent higher rate of peripheral artery disease, most marked in women under 60, and those who have had a blood clot are far more likely than non-inflammatory patients to have another. Neither is a reason for alarm; both are reasons for the usual checks on blood pressure, cholesterol and circulation to actually happen.

The research, by the questions people ask

Getting a diagnosis

Treatment

Living with AS

Beyond the spine